TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07404111: A Study of VV-14305 for the Treatment of Thyroid Eye Disease

Sponsor: Kriya Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 135 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$5,982,640

Rescue Site Savings

+$3,950,800

Unlock Full NCT07404111 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07404111 Rescue Dossier →